A clinical study of Favipiravir compared to Arbidol in COVID-19 patients
Latest Information Update: 24 Mar 2020
At a glance
- Drugs Favipiravir (Primary) ; Umifenovir
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- 24 Mar 2020 New trial record
- 19 Mar 2020 Results(n=240) published in the Zhejiang Hisun Pharmaceutical Media Release.
Most Recent Events
Trial Overview
Purpose
This study will evaluate Favipiravir compared to Arbidol in COVID-19 patients.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Affiliations Zhejiang Hisun Pharmaceutical
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase III
- Location China
- Focus Adverse reactions; Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| FavipiravirPrimary Drug | Oral | Tablet |
| Umifenovir |
-
|
-
|
Favipiravir
Umifenovir(Arbidol)
Results
Therapeutic efficacy
Results from a clinical trial in patients with COVID-2019 infections demonstrated that effectiveness was better in the patients treated with favipiravir than control group patients treated with abidole and was 71.43% and 55.86%, respectively. The same effects were obderved for the average antipyretic and cough remission time [1] .
Publications
-
Zhejiang Hisun Pharmaceutical. Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients. Media-Rel 2020;.
Media Release
Trial Centres
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 24 Mar 2020 | New trial record | New trial record Updated 24 Mar 2020 |
| 19 Mar 2020 | Results | Results(n=240) published in the Zhejiang Hisun Pharmaceutical Media Release. Updated 24 Mar 2020 |
References
-
Zhejiang Hisun Pharmaceutical. Zhejiang Hisun Pharmaceutical Co. Ltd.: Favipiravir Works - Preliminary Clinical Studies Suggest Positive Effects on COVID-19 Patients. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG